Press-release for stocks related to als

Prices are updated after-hours

tags : Als

save search

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute
Published: 2022-02-02 (Crawled : 14:30) - biospace.com/
TCON | $2.13 -6.99% -7.51% 350K

Health Technology

| -22.99% | O: -2.55% H: 0.0% C: 0.0%
trc102 phase 2 als trial lung cancer pons cancer

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
Published: 2021-12-27 (Crawled : 14:00) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K

Health Technology

| -42.11% | O: -9.47% H: 0.0% C: -11.82%
als ongoing trial positive results positive results

TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
TCON | $2.13 -6.99% -7.51% 350K

Health Technology

| -24.91% | O: 0.0% H: 1.78% C: -9.25%
als conference

TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol
Published: 2022-03-10 (Crawled : 14:00) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K

Health Technology

| -14.23% | O: 6.1% H: 0.0% C: 0.0%
fda als fda approval approval

TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
Published: 2022-03-11 (Crawled : 13:30) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K

Health Technology

| -19.16% | O: 10.73% H: 0.0% C: 0.0%
health als thc conference

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
Published: 2022-02-04 (Crawled : 12:30) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 202.86% | O: -2.52% H: 0.0% C: 0.0%
VNDA | $4.97 -5.15% -5.43% 3.9M

Health Technology

| -64.01% | O: -22.12% H: 0.0% C: 0.0%
als report results

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
VNDA | $4.97 -5.15% -5.43% 3.9M

Health Technology

| -63.84% | O: -0.55% H: 0.0% C: 0.0%
hetlioz als patent

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Published: 2022-02-17 (Crawled : 00:00) - prnewswire.com
VNDA | $4.97 -5.15% -5.43% 3.9M

Health Technology

| -61.13% | O: -1.26% H: 1.73% C: 0.75%
als financial results results

Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
Published: 2022-02-03 (Crawled : 13:00) - biospace.com/
MRNS | $1.41 -2.08% -2.13% 4.8M

Health Technology

| -86.49% | O: -3.35% H: 2.28% C: 0.5%
als europe

Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
Published: 2022-01-05 (Crawled : 13:00) - biospace.com/
MRNS | $1.41 -2.08% -2.13% 4.8M

Health Technology

| -88.94% | O: -0.71% H: 2.29% C: -10.27%
health als thc conference j.p. morgan healthcare conference

Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
Published: 2022-02-22 (Crawled : 00:00) - biospace.com/
MRNS | $1.41 -2.08% -2.13% 4.8M

Health Technology

| -87.41% | O: -1.16% H: 2.26% C: 0.99%
epilepticus als trials trial one clinical trials phase 3

Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
MRNS | $1.41 -2.08% -2.13% 4.8M

Health Technology

| -88.25% | O: 0.25% H: 0.83% C: -0.75%
als financial results results

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-21 (Crawled : 12:00) - biospace.com/
MRNS | $1.41 -2.08% -2.13% 4.8M

Health Technology

| -85.9% | O: -10.0% H: 8.22% C: -2.89%
als financial results report results

Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
Published: 2022-02-07 (Crawled : 13:00) - biospace.com/
CYCC | $1.86 -5.1% -5.38% 38K

Health Technology

| -47.65% | O: 0.31% H: 7.81% C: 5.0%
als ceo conference cel

Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
Published: 2021-12-23 (Crawled : 13:00) - biospace.com/
CYCC | $1.86 -5.1% -5.38% 38K

Health Technology

| -55.35% | O: -2.41% H: 9.59% C: 9.59%
als conference cel biotech iot

Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
Published: 2022-01-06 (Crawled : 21:00) - biospace.com/
CYCC | $1.86 -5.1% -5.38% 38K

Health Technology

| -59.56% | O: -1.33% H: 1.84% C: -2.33%
als ces cel

Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
Published: 2022-03-09 (Crawled : 14:00) - biospace.com/
CYCC | $1.86 -5.1% -5.38% 38K

Health Technology

| -48.77% | O: -0.61% H: 6.48% C: 2.16%
health als thc conference cel

Universe Pharmaceuticals INC Announces Strategic Alliance with Kitanihon Pharmaceutical Co., Ltd. to Address the Market Demand for Kampo Medicine and High-end Traditional Chinese Medicine
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
UPC | $2.225 9.61% 8.76% 270K

Manufacturing

| 14.04% | O: 0.56% H: 0.0% C: 0.0%
chinese ema als

Universe Pharmaceuticals INC Reports Fiscal Year 2021 Financial Results
Published: 2022-01-31 (Crawled : 14:30) - biospace.com/
UPC | $2.225 9.61% 8.76% 270K

Manufacturing